Bitcoin price today: tumbles below $90k as Fed cut doubts spark risk-off mood
BeOne Medicines Ltd. (NASDAQ:ONC) SVP, General Counsel, Lee Chan Henry, reported selling a total of 996 American Depositary Shares of the company on November 12, 2025. The sales, conducted under a Rule 10b5-1 trading plan, were executed in two tranches at prices ranging from $348.75 to $350.0, for a total value of $347,770.
On the same day, Lee also exercised options to acquire American Depositary Shares. These transactions involved the exercise of options for 302 shares at $194.47, 398 shares at $213.32 and 296 shares at $159.03, resulting in a total value of $190704.
Following these transactions, Lee directly owns 223106 ordinary shares and no American Depositary Shares of BeOne Medicines Ltd.
In other recent news, BeOne Medicines reported impressive financial results for the third quarter of 2025. The company announced non-GAAP diluted earnings per share (EPS) of $2.65, significantly exceeding the anticipated $0.80. Additionally, BeOne Medicines surpassed revenue expectations, recording $1.41 billion compared to the forecasted $1.37 billion. These results mark a notable achievement for the company, reflecting strong operational performance. Analysts and investors have taken note of these developments as significant indicators of the company’s current financial health. While the stock price movement is not detailed here, the earnings and revenue figures alone have garnered attention. The recent earnings call highlighted BeOne Medicines’ capacity to outperform market expectations. This financial success positions the company as a noteworthy subject of interest in the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.